Will the UK’s Ambitious Life Sciences Investment Power-Up the Psychedelic Sector?

Will the UK’s Ambitious Life Sciences Investment Power-Up the Psychedelic Sector?

,
As an emerging innovative sector addressing unmet mental health needs, psychedelic drug developers are poised to greatly benefit from the diverse initiatives offered within this package. 
World Psychedelics Day Marks 10 Days to the Beginning of Access to Psychedelic-Assisted Therapies in Australia

World Psychedelics Day Marks 10 Days to the Beginning of Access to Psychedelic-Assisted Therapies in Australia

,
June 20th marks World Psychedelic Day, and for Australians it has special significance psychedelic-assisted therapies in Australia this year.
Healing for All: Warriors of Consciousness Making Ketamine Therapy Accessible

Healing for All: Warriors of Consciousness Making Ketamine Therapy Accessible

Warriors of Consciousness helps individuals struggling with anxiety, PTSD and depression to get access to free ketamine therapy.
The Largest Phase 3 Trial on Psilocybin for Depression Has Kicked Off

The Largest Phase 3 Trial on Psilocybin for Depression Has Kicked Off

,
The largest Phase 3 clinical trial investigating the efficacy and tolerability of psilocybin for treatment-resistant depression (TRD) has finally begun.
psilocybin for depression

Single Dose of Psilocybin Yields Long-Term Depression Remission in Over 50% of Cancer Patients

,
A single 25mg dose of psilocybin paired with psychological support has resulted in 57% of patients.
MEAI: The Non-Hallucinogenic Psychedelic with an 'Enough Switch' for Addictions

MEAI: The Non-Hallucinogenic Psychedelic with an ‘Enough Switch’ for Addictions

,
MEAI seems to function like an “enough switch” in the brain, stopping all further desire for alcohol or cocaine and preventing overuse.
A "Trip-Less" Alternative? Non-Hallucinogenic LSD Analog Shows Promise for Treating Mood Disorders

A “Trip-Less” Alternative? Non-Hallucinogenic LSD Analog Shows Promise for Treating Mood Disorders

,
A non-hallucinogenic LSD analogue may be able to treat mood disorders and chronic stress without the hallucinations.
Oregon psilocybin therapy costs

Oregon’s First Licensed Psilocybin Center Charges $2800 for One Session: Are the Costs Justifiable?

,
Taking an objective look at Oregon's first licensed psilocybin center costs. Is $2800 - $3500 for one session justifiable?
The Biggest Psychedelic News Stories on the Week - May 5

The Biggest Psychedelic News Stories of the Week – May 5

,
The psychedelic news scene continues to be constantly evolving, with new developments emerging from various states across the country.
psychedelic clinical trials

Want to Try Psychedelics in a Clinical Setting? 116 Trials Now Recruiting Volunteers (UPDATED)

,
Here's how to become a research subject for psilocybin, LSD, MDMA, ibogaine, DMT and 5-MeO-DMT studies.